Annual CFF
$201.96 M
-$56.59 M-21.89%
December 31, 2023
Summary
- As of February 8, 2025, INBX annual cash flow from financing activities is $201.96 million, with the most recent change of -$56.59 million (-21.89%) on December 31, 2023.
- During the last 3 years, INBX annual CFF has risen by +$35.51 million (+21.33%).
- INBX annual CFF is now -21.89% below its all-time high of $258.55 million, reached on December 31, 2022.
Performance
INBX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$30.25 M-100.00%
September 30, 2024
Summary
- As of February 8, 2025, INBX quarterly cash flow from financing activities is $0.00, with the most recent change of -$30.25 million (-100.00%) on September 30, 2024.
- Over the past year, INBX quarterly CFF has dropped by -$30.25 million (-100.00%).
- INBX quarterly CFF is now -100.00% below its all-time high of $199.89 million, reached on September 30, 2023.
Performance
INBX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$4.18 M
-$199.89 M-97.95%
September 30, 2024
Summary
- As of February 8, 2025, INBX TTM cash flow from financing activities is $4.18 million, with the most recent change of -$199.89 million (-97.95%) on September 30, 2024.
- Over the past year, INBX TTM CFF has dropped by -$199.89 million (-97.95%).
- INBX TTM CFF is now -98.84% below its all-time high of $359.76 million, reached on September 30, 2023.
Performance
INBX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
INBX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | -100.0% | -98.0% |
| 3 y3 years | +21.3% | -100.0% | -98.3% |
| 5 y5 years | +1435.4% | -100.0% | -98.3% |
INBX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.9% | +141.1% | -100.0% | +100.0% | -98.8% | at low |
| 5 y | 5-year | -21.9% | +366.1% | -100.0% | +100.0% | -98.8% | at low |
| alltime | all time | -21.9% | +1435.4% | -100.0% | +100.0% | -98.8% | +338.0% |
Inhibrx Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $4.18 M(-98.0%) |
| Jun 2024 | - | $30.25 M(-27.0%) | $204.07 M(+37.8%) |
| Mar 2024 | - | $41.43 M(-161.4%) | $148.07 M(+10.8%) |
| Dec 2023 | $201.96 M(-21.9%) | -$67.50 M(-133.8%) | $133.60 M(-62.9%) |
| Sep 2023 | - | $199.89 M(-876.2%) | $359.76 M(+124.3%) |
| Jun 2023 | - | -$25.75 M(-195.5%) | $160.38 M(-34.9%) |
| Mar 2023 | - | $26.96 M(-83.0%) | $246.29 M(-4.7%) |
| Dec 2022 | $258.55 M(+208.6%) | $158.66 M(>+9900.0%) | $258.55 M(+82.9%) |
| Sep 2022 | - | $506.00 K(-99.2%) | $141.38 M(-0.2%) |
| Jun 2022 | - | $60.16 M(+53.4%) | $141.69 M(+16.1%) |
| Mar 2022 | - | $39.22 M(-5.4%) | $122.00 M(+45.6%) |
| Dec 2021 | $83.77 M | $41.48 M(+4959.0%) | $83.77 M(+41.3%) |
| Sep 2021 | - | $820.00 K(-98.0%) | $59.28 M(-69.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | $40.48 M(+3996.9%) | $194.68 M(+13.8%) |
| Mar 2021 | - | $988.00 K(-94.2%) | $171.08 M(+2.8%) |
| Dec 2020 | $166.46 M(+284.2%) | $17.00 M(-87.5%) | $166.46 M(+11.7%) |
| Sep 2020 | - | $136.22 M(+707.2%) | $149.02 M(+1264.9%) |
| Jun 2020 | - | $16.88 M(-564.5%) | $10.92 M(-63.5%) |
| Mar 2020 | - | -$3.63 M(+727.6%) | $29.90 M(-31.0%) |
| Dec 2019 | $43.33 M(+229.4%) | -$439.00 K(-76.7%) | $43.33 M(-1.0%) |
| Sep 2019 | - | -$1.89 M(-105.3%) | $43.77 M(-4.1%) |
| Jun 2019 | - | $35.85 M(+266.1%) | $45.65 M(+169.6%) |
| Mar 2019 | - | $9.79 M(+37.3%) | $16.93 M(+214.7%) |
| Dec 2018 | $13.15 M(-2.8%) | - | - |
| Jun 2018 | - | $7.13 M(-506.6%) | $5.38 M(-406.6%) |
| Mar 2018 | - | -$1.75 M | -$1.75 M |
| Dec 2017 | $13.54 M | - | - |
FAQ
- What is Inhibrx Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Inhibrx Biosciences?
- What is Inhibrx Biosciences annual CFF year-on-year change?
- What is Inhibrx Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Inhibrx Biosciences?
- What is Inhibrx Biosciences quarterly CFF year-on-year change?
- What is Inhibrx Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Inhibrx Biosciences?
- What is Inhibrx Biosciences TTM CFF year-on-year change?
What is Inhibrx Biosciences annual cash flow from financing activities?
The current annual CFF of INBX is $201.96 M
What is the all time high annual CFF for Inhibrx Biosciences?
Inhibrx Biosciences all-time high annual cash flow from financing activities is $258.55 M
What is Inhibrx Biosciences annual CFF year-on-year change?
Over the past year, INBX annual cash flow from financing activities has changed by -$56.59 M (-21.89%)
What is Inhibrx Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of INBX is $0.00
What is the all time high quarterly CFF for Inhibrx Biosciences?
Inhibrx Biosciences all-time high quarterly cash flow from financing activities is $199.89 M
What is Inhibrx Biosciences quarterly CFF year-on-year change?
Over the past year, INBX quarterly cash flow from financing activities has changed by -$30.25 M (-100.00%)
What is Inhibrx Biosciences TTM cash flow from financing activities?
The current TTM CFF of INBX is $4.18 M
What is the all time high TTM CFF for Inhibrx Biosciences?
Inhibrx Biosciences all-time high TTM cash flow from financing activities is $359.76 M
What is Inhibrx Biosciences TTM CFF year-on-year change?
Over the past year, INBX TTM cash flow from financing activities has changed by -$199.89 M (-97.95%)